SG3 Management’s Profound Medical PROF Stock Holding History

SG3 Management’s Portfolio PROF Stock Details PROF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-37,500	Closed	-$614K	–	1195
2021 Q2	$614K	Buy	37,500 +7,500	+25%	+$140K	0.02%	608
2021 Q1	$604K	Sell	30,000 -1,000	-3%	-$24K	0.02%	725
2020 Q4	$637K	Buy	31,000 +17,520	+130%	+$322K	0.01%	676
2020 Q3	$238K	Buy	+13,480	New	+$214K	0.01%	698

Other funds holding PROF

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

LBA

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SG3 Management's PROF Position: Q3 2021 in Review

SG3 Management sold out of Profound Medical (PROF) in Q3 2021, closing a stake of 37,500 shares — an estimated $614K sold.

SG3 Management first reported a position in PROF in Q3 2020 and held it in 4 quarters. The position peaked at $637K in Q4 2020. 46 funds tracked by Wall St. Rank hold PROF as of Q3 2021.

SG3 Management reported no remaining Profound Medical position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 37,500 Profound Medical shares in Q3 2021, an estimated $614K.
SG3 Management first reported a position in Profound Medical in Q3 2020 and held it in 4 quarters.
SG3 Management's Profound Medical position peaked at $637K in Q4 2020.
46 funds tracked by Wall St. Rank held Profound Medical as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.